Changes Made to Phase 3 Xtandi Trial in Men with Non–Metastatic Castration–Resistant Prostate Cancer

Changes Made to Phase 3 Xtandi Trial in Men with Non–Metastatic Castration–Resistant Prostate Cancer
Astellas Pharma and Pfizer amended the protocol of the international Phase 3 PROSPER trial evaluating Xtandi (enzalutamide) in men with non–metastatic castration–resistant prostate cancer (CRPC). PROSPER is a randomized, double–blind, placebo–controlled trial (NCT02003924) that is evaluating the safety and effectiveness of Xtandi in these patients. Study participants are randomized to 160 mg of Xtandi orally once daily or a placebo. The primary goal

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *